Scaling AI Across the Healthcare Value Chain: From Experimentation to Deployable Impact in Pharma, MedTech, and Health Technology

OVERVIEW

AI has moved from innovation agenda to operational pressure.

Across pharma, CROs, medtech, and health technology, organisations have run the pilots and secured investment. The challenge now is deployment: why does scaling AI remain so difficult, and what are the organisations making real progress doing differently?

The barriers are rarely technical alone. Fragmented data environments, evolving regulation across the MHRA, FDA, and EU AI Act, growing evidence requirements, and the challenge of embedding AI into trusted clinical and commercial workflows continue to slow adoption.

The organisations moving fastest are not always the most experimental. They are the ones building the operational foundations deployment requires: scalable data infrastructure, governance that supports both compliance and pace, validation strategies that generate real evidence, and partnerships focused on adoption rather than pilots.

This discussion brings together senior leaders from across the healthcare value chain to explore what is genuinely enabling AI deployment in the UK today…and what still stands in the way.

Discussion Themes

• Where AI is already delivering measurable value and where deployment gaps remain largest
• How organisations are navigating regulatory complexity without slowing innovation
• What validation, explainability, and transparency actually require in practice
• The role of real-world data and cross-sector partnerships in moving from pilot to deployment
• How health systems are evolving as buyers of AI - and what this means commercially
• What the next three to five years look like for organisations that scale successfully